🩺 It serves as a platform for ordering appointments, prescriptions, video consultations and e-consultations
🚨 $PSKY MedTech 🚨
🩺 Provides a healthcare CRM software
📈 Sales are set to grow by 38% YoY from 2020 to 2021
⚡️ Developing a platform for third-parties to commercialise their MedTech apps and integrate these with PatientSky’s software
✅ Becoming a Platform-as-a-Service
🩺 It serves as a platform for ordering appointments, prescriptions, video consultations and e-consultations
🥼 And it added a myriad of possibilities along the way, starting from a simple EHR management tool to a MedTech platform
2️⃣ By 2019, it counted over 1m app downloads and added an insurance module, Electronic Health Records (EHR) and a medication tool
3️⃣ By 2020, it expanded into hospitals and counted over 1.8m app downloads
PatientSky’s offering is made of a Patient management tool and a MetTech Platform
🚩 The EHR-landscape offers little differentiation possibilities and is regulated
✅ PatientSky therefor choose to build its advantage on top of its “platform offering”
This is a conventional Electronic Health Records software, enabling clinics and hospitals to track their patient’s health
It also enables medical staff to arrange their patient’s bookings, book e-visits and sort out their patient’s medications
· Used by over 25,000 practitioners and over 4,800 clinics
· Used most by General Practitioners, Physiotherapists and Psychologists
💊 Reducing prescription errors by op to 70%
💸 Reduces yearly costs by NOK 78k per clinic on average
📲 Their mobile app reduces inbound calls with 54%
✅ PatientSky and other alternatives are cloud-based and can be customised to a greater extent to the physician’s needs
The market for patient management tools / healthcare CRM tools is crowded with (local) alternatives
⚖️ Each software has to comply with local rules in order to be eligible for state-reimbursements
📟 Providing a No-Code / Low-Code platform to other MedTech developers and clinics
🔥 Enabling these to build an app 100% customised to their own needs
· Patient communications
· Security (patient verification, authority delegation, encryption)
· Internationalisation (translation, cross-border EHR)
· Mobile & apps
· Compliance (Secure file storage, audit tracking)
· Hosting services and data-base management services
· Data migration
· Enterprise business intelligence integration
✅ Effectively creating an ecosystem of healthcare-focussed apps for patient management
🩺 The platform currently offers over 60 services
1️⃣ PatientSky’s SaaS-tool generates all of the NOK 170m in sales for 2020
2️⃣ It plans to monetise its app into 2021 in order to generate additional sales
3️⃣ The PaaS platform might start providing “additional upside” going into 2021
🌐 According to Grand View Research, the healthcare CRM market is set to reach $ 17.8B by 2025, a CAGR of 9.1% over the 2014 - 2025 period
https://t.co/k6ahm02zWV
📈 Driven by the increase in the number of hospitals & inclination towards automated workflows
https://t.co/HIIhqn0Laf
📈 Driven by the need to increase practice-efficiency and increase the practitioner’s time spent with patients
https://t.co/lFzjlj8BQz
🏛 But governments are constantly raising the bar for software to be eligible for subsidies
🏰 Raising the barrier to entries and chasing away smaller, local solutions
✅ Infodoc provides EHR, billing modules and appointment scheduling
💸 It paid $ 32m and Infodoc had sales of around $ 6.7m and is debt-free, for an EV / Sales of around 5
✅ PatientSky generates $ 20m a year in sales through its cloud-based patient management tool
🔥 It plans to monetise its app, which has been downloaded 1.8m times by 2020 (vs 1m in 2019)
Johan Zetterström, Group CEO of PatientSky
📈 Sales grew 26% form 2019 to 2020 and are expected to grew 38% from 2020 to 2021
💵 Operating expenses stood at 110% of sales for H1 ’20 vs 134% in 2019
💎 EBITDA margins stood at 15% in 2019 and are expected to reach 35% in 2020
✅ Market of patient management is growing by around 10% a year over 2020 - 2025 period as population is ageing
✅ Market is further driven by increasing efficiency and digitisation requirements, in part boosted by regulation
✅ It also counts 1.8m download for its app (which enables users to book appointments) and plans to monetise it
✅ Using apps proposed by third-parties on the PatientSky platform, developers and practitioners can build their own fully-integrated and customised solution
🚩 Market for healthcare CRM tools is fragmented and depends heavily on local regulations
🔥 We stay on the sidelines for now and wait for PatientSky to show commercial progress with its PaaS platform
🔮 $SF.ST is on our watchlist 👉 Coming SOON 🔮
Sources
✑ Investor presentation
✑ Company website
✑ Mordor Intelligence
✑ Grand View Research
✑ Market Research Future
✅ For more content, follow us on Twitter 🔥
✅ EASY BRIEFINGS delivered straight to your inbox 📩 Don’t MISS IT 👇
https://t.co/lQ6ay1zmm2
More from Software
Kubernetes vs Serverless offerings
Why would you need Kubernetes when there are offerings like Vercel, Netlify, or AWS Lambda/Amplify that basically manage everything for you and offer even more?
Well, let's try to look at both approaches and draw our own conclusions!
🧵⏬
1️⃣ A quick look at Kubernetes
Kubernetes is a container orchestrator and thus needs containers to begin with. It's a paradigm shift to more traditional software development, where components are developed, and then deployed to bare metal machines or VMs.
There are additional steps now: Making sure your application is suited to be containerized (12-factor apps, I look at you: https://t.co/nuH4dmpUmf), containerizing the application, following some pretty well-proven standards, and then pushing the image to a registry.
After all that, you need to write specs which instruct Kubernetes what the desired state of your application is, and finally let Kubernetes do its work. It's certainly not a NoOps platform, as you'll still need people knowing what they do and how to handle Kubernetes.
⏬
2️⃣ A quick look at (some!) serverless offerings
The offer is pretty simple: You write the code, the platform handles everything else for you. It's basically leaning far to the NoOps side. There is not much to manage anymore.
Take your Next.js / Nuxt.js app, point the ...
Why would you need Kubernetes when there are offerings like Vercel, Netlify, or AWS Lambda/Amplify that basically manage everything for you and offer even more?
Well, let's try to look at both approaches and draw our own conclusions!
🧵⏬
1️⃣ A quick look at Kubernetes
Kubernetes is a container orchestrator and thus needs containers to begin with. It's a paradigm shift to more traditional software development, where components are developed, and then deployed to bare metal machines or VMs.
There are additional steps now: Making sure your application is suited to be containerized (12-factor apps, I look at you: https://t.co/nuH4dmpUmf), containerizing the application, following some pretty well-proven standards, and then pushing the image to a registry.
After all that, you need to write specs which instruct Kubernetes what the desired state of your application is, and finally let Kubernetes do its work. It's certainly not a NoOps platform, as you'll still need people knowing what they do and how to handle Kubernetes.
⏬
2️⃣ A quick look at (some!) serverless offerings
The offer is pretty simple: You write the code, the platform handles everything else for you. It's basically leaning far to the NoOps side. There is not much to manage anymore.
Take your Next.js / Nuxt.js app, point the ...
You May Also Like
https://t.co/6cRR2B3jBE
Viruses and other pathogens are often studied as stand-alone entities, despite that, in nature, they mostly live in multispecies associations called biofilms—both externally and within the host.
https://t.co/FBfXhUrH5d
Microorganisms in biofilms are enclosed by an extracellular matrix that confers protection and improves survival. Previous studies have shown that viruses can secondarily colonize preexisting biofilms, and viral biofilms have also been described.
...we raise the perspective that CoVs can persistently infect bats due to their association with biofilm structures. This phenomenon potentially provides an optimal environment for nonpathogenic & well-adapted viruses to interact with the host, as well as for viral recombination.
Biofilms can also enhance virion viability in extracellular environments, such as on fomites and in aquatic sediments, allowing viral persistence and dissemination.
Viruses and other pathogens are often studied as stand-alone entities, despite that, in nature, they mostly live in multispecies associations called biofilms—both externally and within the host.
https://t.co/FBfXhUrH5d
Microorganisms in biofilms are enclosed by an extracellular matrix that confers protection and improves survival. Previous studies have shown that viruses can secondarily colonize preexisting biofilms, and viral biofilms have also been described.
...we raise the perspective that CoVs can persistently infect bats due to their association with biofilm structures. This phenomenon potentially provides an optimal environment for nonpathogenic & well-adapted viruses to interact with the host, as well as for viral recombination.
Biofilms can also enhance virion viability in extracellular environments, such as on fomites and in aquatic sediments, allowing viral persistence and dissemination.
@franciscodeasis https://t.co/OuQaBRFPu7
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the
chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project
starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".
P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!
https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the
chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project
starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".
P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!
https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?